Browse > Article

Inhibitory Effects of Onchungeum on Cytokine Production from Phytohaemagglutinin-stimulated Peripheral blood Mononuclear cells of Behcets Patients  

Lim Hong Jin (Department of Opthamalogy Otoiaryngology and Dermatology, Oriental Medical Collage, Wonkwang University)
Hwang Choong Yeon (Department of Opthamalogy Otoiaryngology and Dermatology, Oriental Medical Collage, Wonkwang University)
Chiang Hsueh Chuan (Department of Opthamalogy Otoiaryngology and Dermatology, Oriental Medical Collage, Wonkwang University)
Kim Nam Kwon (Department of Opthamalogy Otoiaryngology and Dermatology, Oriental Medical Collage, Wonkwang University)
Kwon Il Ho (Department of Opthamalogy Otoiaryngology and Dermatology, Oriental Medical Collage, Wonkwang University)
Publication Information
Journal of Physiology & Pathology in Korean Medicine / v.16, no.4, 2002 , pp. 768-773 More about this Journal
Abstract
Behcets disease is a systemic inflammatory disorder. The etiology and pathogenesis of Behcets disease has yet been fully elucidated but might involve immune dysfunction. Cytokines involved in the regulation of inflammatory reactions and immune responses may play a role in the pathogenesis of Behcets disease (BD). Onchungeum is an Oriental herbal medication, which has been successfully used in Korea for the treatment of BD. This report describes modulation effects of Onchungeum on cytokine production from phytohaemagglutinin (PHA)-stimulated peripheral blood mononuclear cells (PBMC) of Behcets patients by ELISA. Onchungeum significantly inhibited the production of pro-inflammatory cytokines. TNF-α and IL-1β, compared to absence of Onchungeum (by 52.3 1.4 % inhibition for TNF-α and 113.5 3.3 % for IL-1β, p < 0.001). Onchungeum also inhibited the production of IFN-γ, immunoregulatory Th1 cytokine, by 89.4 0.8 % (p < 0.001). The inhibitory effects of Onchungeum on cytokine production showed dose-dependent manner, and the pre-treatment of 1 mg/ml Onchungeum had better effects than immunosuppressive drug for treatment of BD, cyclosporin A. Our results suggest that Onchungeum treatment for Behcets disease patients may have pharmacologic activities and abilities of regulation of immune and inflammatory responses by cytokine modulation.
Keywords
onchungeum; cytokine; Behcets;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Behcet씨 證候群의 臨床的 硏究 /
[ 김종남 ] / 이화의대지
2 The combination of tumor necrosis factor- blockade with interleukin-1 and interleukin-17 blockade is more effective for controlling synovial inflammation and bone resorption in an ex vivo model. /
[ Chabaud M;Miossec P. ] / Arthritis Rheum   ScienceOn
3 Behcet's disease. /
[ Sakane T;Takeno M;Suzuki N;Inaba G ] / N Engl J Med   ScienceOn
4 Intermittent and periodic arthritic syndromes. /
[ Kastner DL.;Koopman WJ(Ed.) ] / Arthritis and allied conditions: a textbook of rheumatology.
5 Behcet's disease. /
[ Kaklamani VG;Vaiopoulos G;Kaklamanis PG. ] / Semin, Arthritis Rheum   ScienceOn
6 Behcet Disease. /
[ Shimizu, T.;Ehrlich, G.E.; Inaba, G.(et, al) ] / Seminars in Arthritis and Rheumatism.   ScienceOn
7 /
[ 何任(主編) ] / 금괘요략講義
8 /
[ 襲廷賢 ] / 增補萬病回春(下卷)
9 /
[ 洪元植 ] / 中國醫學史
10 /
[ 康秉秀 ] / 漢方臨床알레르기
11 /
[ 裵元植 ] / 增補最新漢方臨床學
12 Elevated serum interleukin 1 receptors and interleukin 1b in patients with Behcet's disease: Correlations with disease activity and severity. /
[ Yosipovitch G;Shohat B;Bshara J;Wysenbeek A;Weinberger A. ] / Isr J Med Sci
13 Overproduction of monocyte derived tumor necrosis factor , interleukin (IL) 6, IL-8 and increased neutrophil superoxide generation in Behcet's disease. A comparative study with familial Mediterranean fever and healthy subjects. /
[ Mege JL;Dilsen N;Sanguedolce V;Gul A;Bongrand P;Roux H(et al.) ] / J Rheumatol
14 Cytokines in Behcet's disease. /
[ Sayinalp N;zcebe OI;zdemir O;Haznedaro lu IC;Dundar S, Kirazli ] / J Rheumatol
15 中西醫結合治療白塞病療效觀察 /
[ 吳之伍(外) ] / 臨床皮膚科 雜誌
16 /
[ 巢元方 ] / 巢氏諸病源候論
17 Low dose cyclosporin A versus plused cyclophosphamide in Behcet's syndrom: a single masked trial. /
[ Ozyazgan Y;Yurdakul S;Yazici H;Tuzun B;Iscimen A;Tuzun Y(et al.) ] / Br J Ophthalmol   ScienceOn
18 Thalidomide selectively inhibits tumor necrosis factor production by stimulated human monocytes. /
[ Sampaio EP;Sarno EN;Galilly R;Cohn ZA;Kaplan G. ] / J Exp Med   ScienceOn
19 The immunosuppressive drug thalidomide induces T helper cell type 2 (Th2) and concomitantly inhibits Th1 cytokine production in mitogen- and antigen-stimulated human peripheral mononuclear cell cultures. /
[ McHugh SM;Rifkin IR;Deighton J;Wilson AB;Lachmann PJ;Lockwood CM(et al.) ] / Clin Exp Immunol   ScienceOn
20 /
[ 이천 ] / 原本編註醫學入門(下)
21 Central nervous system symptoms in patients with Behcet disease receiving cyclosporin therapy. /
[ Kotake S;Higashi K;Yoshikawa K;Sasamoto Y;Okamoto T;Matsuda H. ] / Ophthalmology   ScienceOn
22 /
[ 張介賓 ] / 國譯景岳全書(上)
23 Histological and direct immunofluorescence study of cutaneous hyperreactivity in Behcet disease. /
[ Haim S;Sobel JD;Friedman-Birnbaum R; Lichtig C ] / Br. J. Dermatol.   ScienceOn
24 /
[ 申載鏞 ] / 方藥合編解說
25 /
[ 이천 ] / 醫學入門
26 /
[ 許浚 ] / 原本東醫寶鑑
27 /
[ 辛民敎 ] / 臨床本草學
28 Behcet's disease. New perspectives on an enigmatic syndrome. /
[ Arbesfeld SJ;Kurban AK. ] / J Am Acad Dermatol   ScienceOn
29 /
[ 金定濟 ] / 診療要覽
30 Tumour necrosis factor as a therapeutic target in rheumatoid arthritis and other chronic inflammatory diseases: the clinical experience with infliximab (Remicade). /
[ Bondeson J;Maini RN. ] / Int J Clin Pract
31 /
[ 朴炳坤 ] / 增補韓方臨床40年
32 Anti-tumor necrosis factor monoclonal antibody therapy for gastrointestinal Behcet's disease: Case report. /
[ Hassard PV;Binder SW;Nelson V;Vasiliauskas EA. ] / Gastroenterology   ScienceOn
33 Thalidomide: Current and potential clinical applications. /
[ Calabrese L;Fleischer AB. ] / Am J Med   ScienceOn